PURPOSE: To evaluate the safety and effect on visual function of ciliary neurotrophic factor delivered via an intraocular encapsulated cell implant for the treatment of retinitis pigmentosa (RP). DESIGN:Ciliary neurotrophic factor for late-stage retinitis pigmentosa study 3 (CNTF3; n = 65) and ciliary neurotrophic factorfor early-stage retinitis pigmentosa study 4 (CNTF4; n = 68) were multicenter, sham-controlled dose-ranging studies. METHODS: Patients were randomly assigned to receive a high- or low-dose implant in 1 eye and sham surgery in the fellow eye. The primary endpoints were change in best-corrected visual acuity (BCVA) at 12 months for CNTF3 and change in visual field sensitivity at 12 months for CNTF4. Patients had the choice of retaining or removing the implant at 12 months for CNTF3 and 24 months for CNTF4. RESULTS: There were no serious adverse events related to either the encapsulated cell implant or the surgical procedure. In CNTF3, there was no change in acuity in either ciliary neurotrophic factor- or sham-treated eyes at 1 year. In CNTF4, eyes treated with the high-dose implant showed a significant decrease in sensitivity while no change was seen in sham- and low dose-treated eyes at 12 months. The decrease in sensitivity was reversible upon implant removal. In both studies, ciliary neurotrophic factor treatment resulted in a dose-dependent increase in retinal thickness. CONCLUSIONS: Long-term intraocular delivery of ciliary neurotrophic factor is achieved by the encapsulated cell implant. Neither study showed therapeutic benefit in the primary outcome variable.
RCT Entities:
PURPOSE: To evaluate the safety and effect on visual function of ciliary neurotrophic factor delivered via an intraocular encapsulated cell implant for the treatment of retinitis pigmentosa (RP). DESIGN:Ciliary neurotrophic factor for late-stage retinitis pigmentosa study 3 (CNTF3; n = 65) and ciliary neurotrophic factor for early-stage retinitis pigmentosa study 4 (CNTF4; n = 68) were multicenter, sham-controlled dose-ranging studies. METHODS:Patients were randomly assigned to receive a high- or low-dose implant in 1 eye and sham surgery in the fellow eye. The primary endpoints were change in best-corrected visual acuity (BCVA) at 12 months for CNTF3 and change in visual field sensitivity at 12 months for CNTF4. Patients had the choice of retaining or removing the implant at 12 months for CNTF3 and 24 months for CNTF4. RESULTS: There were no serious adverse events related to either the encapsulated cell implant or the surgical procedure. In CNTF3, there was no change in acuity in either ciliary neurotrophic factor- or sham-treated eyes at 1 year. In CNTF4, eyes treated with the high-dose implant showed a significant decrease in sensitivity while no change was seen in sham- and low dose-treated eyes at 12 months. The decrease in sensitivity was reversible upon implant removal. In both studies, ciliary neurotrophic factor treatment resulted in a dose-dependent increase in retinal thickness. CONCLUSIONS: Long-term intraocular delivery of ciliary neurotrophic factor is achieved by the encapsulated cell implant. Neither study showed therapeutic benefit in the primary outcome variable.
Authors: Kang Zhang; Jill J Hopkins; Jeffrey S Heier; David G Birch; Lawrence S Halperin; Thomas A Albini; David M Brown; Glenn J Jaffe; Weng Tao; George A Williams Journal: Proc Natl Acad Sci U S A Date: 2011-03-28 Impact factor: 11.205
Authors: Yiwen Li; Weng Tao; Lingyu Luo; Deqiang Huang; Konrad Kauper; Paul Stabila; Matthew M Lavail; Alan M Laties; Rong Wen Journal: PLoS One Date: 2010-03-02 Impact factor: 3.240
Authors: Ronald A Bush; Bo Lei; Weng Tao; Dorit Raz; Chi-Chao Chan; Terry A Cox; Maria Santos-Muffley; Paul A Sieving Journal: Invest Ophthalmol Vis Sci Date: 2004-07 Impact factor: 4.799
Authors: Weng Tao; Rong Wen; Moses B Goddard; Sandy D Sherman; Pam J O'Rourke; Paul F Stabila; William J Bell; Brenda J Dean; Konrad A Kauper; Veronica A Budz; William G Tsiaras; Gregory M Acland; Sue Pearce-Kelling; Alan M Laties; Gustavo D Aguirre Journal: Invest Ophthalmol Vis Sci Date: 2002-10 Impact factor: 4.799
Authors: Donald C Hood; Christine E Lin; Margot A Lazow; Kirsten G Locke; Xian Zhang; David G Birch Journal: Invest Ophthalmol Vis Sci Date: 2008-11-14 Impact factor: 4.799
Authors: Roy W Beck; Pamela S Moke; Andrew H Turpin; Frederick L Ferris; John Paul SanGiovanni; Chris A Johnson; Eileen E Birch; Danielle L Chandler; Terry A Cox; R Clifford Blair; Raymond T Kraker Journal: Am J Ophthalmol Date: 2003-02 Impact factor: 5.258
Authors: Alessandro Iannaccone; Stephen B Kritchevsky; Maria Laura Ciccarelli; Salvatore A Tedesco; Claudio Macaluso; William J Kimberling; Grant W Somes Journal: Invest Ophthalmol Vis Sci Date: 2004-03 Impact factor: 4.799
Authors: Songhua Li; Kota Sato; William C Gordon; Michael Sendtner; Nicolas G Bazan; Minghao Jin Journal: J Biol Chem Date: 2018-08-16 Impact factor: 5.157
Authors: Brandon J Lujan; Austin Roorda; Jason A Croskrey; Adam M Dubis; Robert F Cooper; Jan-Kristine Bayabo; Jacque L Duncan; Bhavna J Antony; Joseph Carroll Journal: Retina Date: 2015-08 Impact factor: 4.256
Authors: David G Birch; Lea D Bennett; Jacque L Duncan; Richard G Weleber; Mark E Pennesi Journal: Am J Ophthalmol Date: 2016-07-25 Impact factor: 5.258
Authors: Kun Do Rhee; Steven Nusinowitz; Kevin Chao; Fei Yu; Dean Bok; Xian-Jie Yang Journal: Proc Natl Acad Sci U S A Date: 2013-11-04 Impact factor: 11.205